|Description||BCI is an allosteric inhibitor of dual-specificity phosphatases (DUSP). BCI treatment of DUSP6-Myc-transfected cells suppresses DUSP6 or DUSP1 activity. BCI induces expansion of myocardial progenitors that ultimately increases heart size in zebrafish embryos via inhibiting DUSP6. BCI also inhibits lung cancer and uveal melanoma cells viability (IC50 = 0.1 to 90 μM). DUSP6 functions a feedback regulator of fibroblast growth factor (FGF) signaling to limit the activity of extracellular signal-regulated kinases (ERKs) 1 and 2.|
|Brife Description||DUSP inhibitor|
Levosimendan is a calcium sensitizer acting through calcium-dependent binding to cardiac troponin C (cTnC)
Henagliflozin, a glucoside compound, has been found to be a sodium-glucose transporter 2 inhibitor that could probably be effective in hyperglycaemic. It is und...
Sodium orthovanadate is an alkaline phosphatase and (Na,K)-ATPase inhibitor with IC50 of 10 μM.
Thalidomide was introduced as a sedative drug, immunomodulatory agent and also is investigated for treating symptoms of many cancers. Thalidomide inhibits an E3...
SPI-112Me is a Shp2 PTP inhibitor.
Isovaleramide is an anticonvulsant molecule isolated from Valeriana pavonii, it inhibits the liver alcohol dehydrogenases.
Erlosiban, an iminopyrrolidin derivative, has been found to be a nonpeptide oxytocin receptor antagonist that could probably be used in the treatment of female ...
ASP-1645 is a novel P2Y12 receptor antagonist using as an antiplatelet agent.